Formulary Chapter 5: Infections - Full Section
|
Notes:
Chapter review date: |
Useful Links |
SCAN Guidelines for antibiotic prescribing in the community 2018 |
NICE NG182: Insect bites and stings: antimicrobial prescribing (September 2020) |
NICE NG153: Impetigo: antimicrobial prescribing (February 2020) |
NICE NG152: Leg ulcer infection: antimicrobial prescribing (January 2020) |
NICE NG19: Diabetic foot problems: prevention and management (October 2019) |
NICE NG138: Pneumonia (community-acquired): antimicrobial prescribing (September 2019) |
NICE NG139: Pneumonia (hospital-acquired): antimicrobial prescribing (September 2019) |
NICE NG141: Cellulitis and erysipelas: antimicrobial prescribing (September 2019) |
NICE NG120: Cough (acute): antimicrobial prescribing (February 2019) |
NICE NG114: Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (December 2018) |
NICE NG117: Bronchiectasis (acute exacerbation): antimicrobial prescribing (December 2018) |
NICE NG112: Urinary tract infection (recurrent): antimicrobial prescribing (October 2018) |
NICE NG110: Prostatitis (acute): antimicrobial prescribing (October 2018) |
NICE NG111: Pyelonephritis (acute): antimicrobial prescribing (October 2018) |
NICE NG109: Urinary tract infection (lower): antimicrobial prescribing (October 2018) |
NICE NG95: Lyme Disease (April 2018) |
NICE NG91 Otitis media (acute): antimicrobial prescribing (March 2018) |
NICE NG84 Sore throat (acute): antimicrobial prescribing (January 2018) |
NICE NG79 Sinusitis (acute): antimicrobial prescribing (October 2017) |
BHIVA Guidelines |
Dental Letter Infective Endocarditis March 2019 |
Dorset Guidance:Antibiotic Prophylaxis (AP) prior to Dental Treatment to prevent Infective Endocarditis March 2019 |
SDCEP Antibiotic Prophylaxis Against Infective Endocarditis |
DCHFT: Adult Surgical Antibiotic Treatment Guidelines |
DCHFT: IV antibiotic to oral switch guidelines |
DCHFT: Medical Directorate Antibiotic Treatment Guidelines |
DCHFT: Antibiotic stop / review date and indication policy |
DCHFT: Penicillin allergy ’traffic light’ guideline |
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
05.01 |
Antibacterial drugs
(1,0)
|
|

Table 1. Summary of antibacterial therapy
(0,0)
|
|

Table 2. Summary of antibacterial prophylaxis
(0,0)
|
05.01.01 |
Penicillins
(0,0)
|
05.01.01.01 |
Benzylpenicillin and phenoxymethylpenicillin
(4,0)
|
05.01.01.02 |
Penicillinase-resistant penicillins
(3,0)
|
05.01.01.03 |
Broad-spectrum penicillins
(4,2)
|
05.01.01.04 |
Antipseudomonal penicillins
(1,1)
|
05.01.01.05 |
Mecillinams
(0,0)
|
05.01.02 |
Cephalosporins, carbapenems and other beta-lactums
(0,0)
|
|

Cephalosporins
(0,0)
|
|

Other beta-lactam antibiotics
(0,1)
|
05.01.02.01 |
Cephalosporins
(8,5)
|
05.01.02.02 |
Carbapenems
(3,0)
|
05.01.02.03 |
Other beta-lactums antibiotics
(2,0)
|
05.01.03 |
Tetracyclines
(3,3)
|
|

Tigecycline
(1,0)
|
05.01.04 |
Aminoglycosides
(6,2)
|
05.01.05 |
Macrolides
(6,1)
|
05.01.06 |
Clindamycin
(2,0)
|
05.01.07 |
Some other antibacterials
(3,2)
|
|

Chloramphenicol
(1,0)
|
|

Fosfomycin
(0,0)
|
|

Fusidic acid
(1,0)
|
|

Vancomycin and teicoplanin
(3,0)
|
|

Daptomycin
(1,0)
|
|

Linezolid
(1,0)
|
|

Quinupristin and dalfopristin
(0,1)
|
|

Polymyxins
(2,0)
|
|

Rifaximin
(1,0)
|
|

Fidaxomicin
(1,0)
|
05.01.08 |
Sulphonamides and trimethoprim
(3,0)
|
05.01.09 |
Antituberculosis drugs
(6,9)
|
05.01.10 |
Antileprotic drugs
(1,2)
|
05.01.11 |
Metronidazole and tinidazole
(2,1)
|
05.01.12 |
Quinolones
(7,1)
|
05.01.13 |
Urinary-tract infections
(5,0)
|
05.02 |
Antifungal drugs
(0,2)
|
|

Treatment of fungal infections
(0,0)
|
|

Drugs used in fungal infections
(0,2)
|
05.02.01 |
Triazole antifungals
(6,0)
|
05.02.02 |
Imidazole antifungals
(0,0)
|
05.02.03 |
Polyene antifungals
(2,0)
|
05.02.04 |
Echinocandin antifungals
(3,0)
|
05.02.05 |
Other antifungals
(2,0)
|
05.03 |
Antiviral drugs
(1,0)
|
05.03.01 |
HIV infection
(1,0)
|
|

Nucleoside reverse transcriptase inhibitors
(17,1)
|
|

Protease inhibitors
(9,0)
|
|

Non-nucleoside reverse transcriptase inhibitors
(4,0)
|
|

Other antiretrovirals
(6,1)
|
|

Pharmacokinetic enhancers of anti-retrovirals
(0,0)
|
|

Combination Products
(0,0)
|
05.03.02 |
Herpesvirus infections
(0,1)
|
05.03.02.01 |
Herpes simplex and varicella-zoster infection
(4,1)
|
05.03.02.02 |
Cytomegalovirus infection
(5,0)
|
05.03.03 |
Viral hepatitis
(0,0)
|
05.03.03.01 |
Chronic hepatitis B
(3,3)
|
05.03.03.02 |
Chronic hepatitis C
(10,4)
|
05.03.04 |
Influenza
(3,1)
|
05.03.05 |
Respiratory syncytial virus
(2,0)
|
05.04 |
Antiprotozoal drugs
(0,0)
|
05.04.01 |
Antimalarials
(0,0)
|
|

Treatment of malaria
(0,0)
|
|

Falciparum malaria (treatment)
(0,0)
|
|

Benign malarias (treatment)
(0,0)
|
|

Prophylaxis against malaria
(0,0)
|
|

Specific recommendations
(0,0)
|
|

Artemether with lumefabtrine
(1,0)
|
|

Chloroquine
(1,0)
|
|

Mefloquine
(1,0)
|
|

Primaquine
(1,0)
|
|

Proguanil
(1,1)
|
|

Pyrimethamine
(1,1)
|
|

Quinine
(1,0)
|
|

Tetracyclines
(0,0)
|
05.04.02 |
Amoebicides
(1,2)
|
05.04.03 |
Trichomonacides
(1,0)
|
05.04.04 |
Antigiardial drugs
(1,1)
|
05.04.05 |
Leishmaniacides
(0,1)
|
05.04.06 |
Trypanocides
(0,0)
|
05.04.07 |
Drugs for toxoplasmosis
(2,0)
|
05.04.08 |
Drugs for pneumocystis pneumonia
(2,0)
|
|

Treatment
(0,0)
|
|

Prophylaxis
(0,0)
|
05.05 |
Anthelmintics
(0,0)
|
05.05.01 |
Drugs for threadworms
(1,1)
|
05.05.02 |
Ascaricides
(0,0)
|
05.05.03 |
Drugs for tapeworm infections
(0,1)
|
|

Taenicides
(0,0)
|
|

Hydatid disease
(0,0)
|
05.05.04 |
Drugs for hookworms
(0,0)
|
05.05.05 |
Schistosomicides
(1,0)
|
05.05.06 |
Filaricides
(0,0)
|
05.05.07 |
Drugs for cutaneous larva migrans
(0,1)
|
05.05.08 |
Drugs for strongyloidiasis
(0,0)
|
05.06 |
Faecal Microbiota Transplant
(1,0)
|